Avalon/GSK Incubation Project Launches First Company, Focused On Celiac Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
New company Sitari will try to develop first drug therapy for celiac disease. Portfolio companies launched by GSK and Avalon also will have their own, dedicated CRO-like organization to handle much of their work.
You may also be interested in...
GSK Buys One Of Eight Firms Formed In VC Partnership With Avalon
Celiac disease specialist Sitari was the first company formed under the six-year collaboration. Three were shut down and Avalon controls the other four, which aren't compatible with GSK's new R&D focus.
India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
QUOTED. 5 March 2021. Dedi Gilad.
Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: